{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:18:42Z","timestamp":1770509922904,"version":"3.49.0"},"reference-count":37,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.3892\/mmr.2017.7211","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T06:30:39Z","timestamp":1502346639000},"page":"4545-4552","source":"Crossref","is-referenced-by-count":10,"title":["Lercanidipine attenuates angiotensin II-induced cardiomyocyte hypertrophy by blocking calcineurin-NFAT3 and CaMKII-HDAC4 signaling"],"prefix":"10.3892","volume":"16","author":[{"given":"Yuezhang","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoliang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianbing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunzeng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianzhou","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,8,10]]},"reference":[{"key":"key20180108003457_b1-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1067\/mhj.2000.111112","article-title":"Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension","volume":"140","author":"Brown","year":"2000","journal-title":"Am Heart J"},{"key":"key20180108003457_b2-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/eurheartj\/ehm605","article-title":"Left ventricular mass predicts heart failure not related to previous myocardial infarction: The Cardiovascular Health Study","volume":"29","author":"de Simone","year":"2008","journal-title":"Eur Heart J"},{"key":"key20180108003457_b3-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.bbrc.2004.07.121","article-title":"Calcium-calcineurin signaling in the regulation of cardiac hypertrophy","volume":"322","author":"Wilkins","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180108003457_b4-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","article-title":"Pathophysiology of cardiac hypertrophy and heart failure: Signaling pathways and novel therapeutic targets","volume":"89","author":"Tham","year":"2015","journal-title":"Arch Toxicol"},{"key":"key20180108003457_b5-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.yjmcc.2011.01.012","article-title":"CaMKII in myocardial hypertrophy and heart failure","volume":"51","author":"Anderson","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"key20180108003457_b6-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0092-8674(00)81573-1","article-title":"A calcineurin-dependent transcriptional pathway for cardiac hypertrophy","volume":"93","author":"Molkentin","year":"1998","journal-title":"Cell"},{"key":"key20180108003457_b7-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1172\/JCI27438","article-title":"CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy","volume":"116","author":"Backs","year":"2006","journal-title":"J Clin Invest"},{"key":"key20180108003457_b8-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"35078","DOI":"10.1074\/jbc.M707083200","article-title":"CaMKIIdelta isoforms differentially affect calcium handling but similarly regulate HDAC\/MEF2 transcriptional responses","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"key20180108003457_b9-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"key":"key20180108003457_b10-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.109.136655","article-title":"Regression of left ventricular mass by antihypertensive treatment: A meta-analysis of randomized comparative studies","volume":"54","author":"Fagard","year":"2009","journal-title":"Hypertension"},{"key":"key20180108003457_b11-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/080370598438998","article-title":"Lercanidipine: Short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties","volume":"2","author":"Herbette","year":"1998","journal-title":"Blood Press Suppl"},{"key":"key20180108003457_b12-mmr-16-04-4545","first-page":"173","article-title":"Lercanidipine in hypertension","volume":"1","author":"Borghi","year":"2005","journal-title":"Vasc Health Risk Manag"},{"key":"key20180108003457_b13-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/00005344-200304000-00006","article-title":"Effect of different dihydropyridine-type Ca2+ antagonists on left ventricle hypertrophy and coronary changes in spontaneously hypertensive rats","volume":"41","author":"Tomassoni","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"key20180108003457_b14-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1161\/01.HYP.0000070116.11304.23","article-title":"Effect of treatment with lercanidipine on heart of Cohen-Rosenthal diabetic hypertensive rats","volume":"41","author":"Amenta","year":"2003","journal-title":"Hypertension"},{"key":"key20180108003457_b15-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.yjmcc.2012.08.005","article-title":"Ca(2+) influx through L-type Ca(2+) channels and transient receptor potential channels activates pathological hypertrophy signaling","volume":"53","author":"Gao","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"key20180108003457_b16-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20180108003457_b17-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/01.HYP.0000205833.89478.5b","article-title":"Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II","volume":"47","author":"Yamamoto","year":"2006","journal-title":"Hypertension"},{"key":"key20180108003457_b18-mmr-16-04-4545","first-page":"H324","article-title":"Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats","volume":"259","author":"Baker","year":"1990","journal-title":"Am J Physiol"},{"key":"key20180108003457_b19-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/01.CIR.103.5.670","article-title":"Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure","volume":"103","author":"Haq","year":"2001","journal-title":"Circulation"},{"key":"key20180108003457_b20-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1161\/01.RES.0000069686.31472.C5","article-title":"The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure","volume":"92","author":"Zhang","year":"2003","journal-title":"Circ Res"},{"key":"key20180108003457_b21-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1073\/pnas.0813013106","article-title":"The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload","volume":"106","author":"Backs","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"key20180108003457_b22-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1006\/bbrc.2000.2893","article-title":"Cardiac calcineurin during transition from hypertrophy to heart failure in rats","volume":"273","author":"Hayashida","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180108003457_b23-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/01.RES.84.6.722","article-title":"Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats","volume":"84","author":"Zhang","year":"1999","journal-title":"Circ Res"},{"key":"key20180108003457_b24-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","article-title":"Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"key":"key20180108003457_b25-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1211\/0022357991772844","article-title":"Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues","volume":"51","author":"Angelico","year":"1999","journal-title":"J Pharm Pharmacol"},{"key":"key20180108003457_b26-mmr-16-04-4545","first-page":"15","article-title":"Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine","volume":"46","author":"Guarneri","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"key20180108003457_b27-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1440-1681.2005.04265.x","article-title":"Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca2+ channel antagonist lercanidipine in human cardiovascular tissue","volume":"32","author":"Brixius","year":"2005","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"key20180108003457_b28-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1097\/00004872-199816120-00017","article-title":"Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators","volume":"16","author":"Omboni","year":"1998","journal-title":"J Hypertens"},{"key":"key20180108003457_b29-mmr-16-04-4545","first-page":"375","article-title":"Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension","volume":"12","author":"Barbagallo","year":"2000","journal-title":"Aging (Milano)"},{"key":"key20180108003457_b30-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0895-7061(03)00901-4","article-title":"Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension","volume":"16","author":"Fogari","year":"2003","journal-title":"Am J Hypertens"},{"key":"key20180108003457_b31-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.HYP.0000058003.27729.5A","article-title":"Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension","volume":"41","author":"Grassi","year":"2003","journal-title":"Hypertension"},{"key":"key20180108003457_b32-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1067\/mcp.2002.127110","article-title":"Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: A randomized, prospective crossover study","volume":"72","author":"Rachmani","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"key20180108003457_b33-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.atherosclerosis.2012.12.005","article-title":"Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide\/interferon-\u03b3-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities","volume":"226","author":"Yeh","year":"2013","journal-title":"Atherosclerosis"},{"key":"key20180108003457_b34-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/01.HYP.35.3.775","article-title":"Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats","volume":"35","author":"Sabbatini","year":"2000","journal-title":"Hypertension"},{"key":"key20180108003457_b35-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00005344-200201000-00005","article-title":"Effects of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats","volume":"39","author":"Sabbatini","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"key20180108003457_b36-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.expneurol.2016.10.014","article-title":"Neuroprotective effect of lercanidipine in middle cerebral artery occlusion model of stroke in rats","volume":"288","author":"Gupta","year":"2016","journal-title":"Exp Neurol"},{"key":"key20180108003457_b37-mmr-16-04-4545","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10571-011-9649-6","article-title":"Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP","volume":"31","author":"Sakurai-Yamashita","year":"2011","journal-title":"Cell Mol Neurobiol"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T01:15:33Z","timestamp":1515374133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2017.7211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,10]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,8,10]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.3892\/mmr.2017.7211"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2017.7211","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,10]]}}}